Humacyte (HUMA) has issued an update.
Humacyte, Inc. has launched an underwritten public offering of 13.4 million shares at $3.00 per share, with an option for underwriters to purchase an additional 2.01 million shares. The anticipated net proceeds are roughly $37.4 million or $43.1 million if the option is fully exercised. This offering, expected to close by March 5, 2024, is part of a previously declared effective shelf registration statement. The company’s press releases regarding the offering’s commencement and pricing were reported but are not considered filed under securities law.
For a thorough assessment of HUMA stock, go to TipRanks’ Stock Analysis page.
